Long‑term remission of prostate cancer with extensive bone metastases upon immuno‑ and virotherapy: A case report

Schirrmacher,Volker; Bihari,Akos‑Sigmund; Stücker,Wilfried; Sprenger,Tobias

doi:10.3892/ol.2014.2588

Long‑term remission of prostate cancer with extensive bone metastases upon immuno‑ and virotherapy: A case report

Authors:
- Volker Schirrmacher
- Akos‑Sigmund Bihari
- Wilfried Stücker
- Tobias Sprenger
View Affiliations

Affiliations: Immunological and Oncological Center, Cologne, Germany
Published online on: October 6, 2014 https://doi.org/10.3892/ol.2014.2588
Pages: 2403-2406

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study reports the case of a patient with hormone‑refractory metastatic prostate cancer who had failed standard therapy, but then achieved complete remission following combined treatment with local hyperthermia (LHT), Newcastle disease virus and dendritic cell (DC) vaccination, which was an unusual combination. In August 2005, the patient underwent a radical prostatectomy. Despite standard treatment, the patient developed progressive bone metastases and stopped conventional therapy in June 2007. Starting in October 2007, the patient was treated with LHT, oncolytic virotherapy and DC vaccination. Prostate‑specific antigen (PSA)‑levels, with the highest level of 233.8 ng/ml in January 2008, decreased to 0.8 ng/ml in late February 2008. In March 2008, a reduction in bone metastases could be detected by positron emission tomography/computed tomography. Since then, the PSA levels have remained low and the patient is doing well. The treatment induced a long‑lasting antitumor memory T‑cell response. This possibly explains the long‑term effectiveness of this novel experimental combined treatment approach.

View Figures

View References

1	Robert-Koch Institut. The Federal Health Monitoring-Prostate Diseases. Robert Kock-Institut; Berlin: pp. 362007
2	Eisenberg DP, Carpenter SG, Adusumilli PS, Chan MK, Hendershott KJ, Yu Z and Fong Y: Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway. Surgery. 148:325–334. 2010.
3	Dendreon Press Release: FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer. http://http://investor.dendreon.com/releasedetail.cfm?ReleaseID=533434. Accessed August 7, 2013
4	Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW and Schellhammer PF; IMPACT study investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411–422. 2010.
5	Draube A, Klein-González N, Mattheus S, Brillant C, Hellmich M, Engert A and von Bergwelt-Baildon M: Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One. 6:e188012011.
6	Fournier P, Bian H, Szeberényi J and Schirrmacher V: Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation. Methods Mol Biol. 797:177–204. 2012.
7	Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R and Riess H: The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 43:33–56. 2002.
8	Rao W, Deng ZS and Liu J: A review of hyperthermia combined with radiotherapy/chemotherapy on malignant tumors. Crit Rev Biomed Eng. 38:101–116. 2010.
9	Schirrmacher V, Fournier P and Schlag P: Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. Expert Rev Vaccines. 13:117–130. 2014.
10	Gulley JL, Madan RA and Schlom J: Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol. 18:e150–e157. 2011.
11	Wilt TJ, Brawer MK, Jones KM, et al: Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 367:203–213. 2012.
12	Chang E, Chalikonda S, Friedl J, Xu H, Phan GQ, Marincola FM, Alexander HR and Bartlett DL: Targeting vaccinia to solid tumors with local hyperthermia. Hum Gene Ther. 16:435–444. 2005.
13	Workenhe ST and Mossman KL: Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther. 22:251–256. 2014.
14	Hou W, Zhang Q, Yan Z, Chen R, Zeh HJ III, Kang R, Lotze MT and Tang D: Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis. 4:e9662013.
15	Knippertz I, Stein MF, Dörrie J, Schaft N, Müller I, Deinzer A, Steinkasserer A and Nettelbeck DM: Mild hyperthermia enhances human monocyte-derived dendritic cell functions and offers potential for applications in vaccination strategies. Int J Hyperthermia. 27:591–603. 2011.
16	Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H and Riley D; CARE Group. The CARE guidelines: consensus-based clinical case report guideline development. J Clin Epidemiol. 67:46–51. 2014.